IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 2, December 2025
Impact Factor: 7.67

Agmatine: Multi-Target Pharmacological Actions and Therapeutic Potential of a Novel Biogenic Amine

Ms.Vaishnavi S. Wankhade[1],Ms. Sakshi A. Ekade[1], Ms. Sakshi D. Wawage[1], Ms. Nandini P. Lokhande[1], Mr. Sharukh Khan Ameen Khan[2], Mr.Vishal B. Rajguru[2], Dr. Vijay S. Borkar[3]
Student, Department of Pharmacology[1]
Assistant Professor, Department of Pharmacology[2]
Principal[3]
Shri Sant Gajanan Maharaj College of Pharmacy, Buldhana, Maharashtra, India
Corresponding Author: Mr. Vishal B. Rajguru
vishalrajguru4@gmail.com

Abstract: *Agmatine, a naturally occurring biogenic amine synthesized from the amino acid arginine, has garnered significant attention due to its diverse physiological effects and therapeutic potential. It is primarily produced through the decarboxylation of arginine by the enzyme arginine decarboxylase and is metabolized by enzymes such as agmatinase. Agmatine has been identified as a neuromodulator, influencing several neurotransmitter systems, including NMDA receptors, imidazoline receptors, and nitric oxide pathways, which contribute to its neuroprotective, anti-inflammatory, and antioxidant properties. Additionally, agmatine exerts vasodilatory effects and has been shown to regulate blood pressure, offering potential benefits for cardiovascular health. Recent studies suggest its therapeutic potential in treating neurological disorders such as depression, anxiety, Alzheimer's disease, and stroke, as well as metabolic disorders like diabetes, through mechanisms involving insulin sensitivity and glucose metabolism. Despite promising preclinical and clinical data, the safety profile and optimal therapeutic dosages of agmatine remain areas of ongoing investigation. This review highlights the multifaceted roles of agmatine, examining its biosynthesis, pharmacological actions, and the emerging therapeutic applications across various medical conditions, while also identifying gaps in research and directions for future studies.*

Keywords: Agmatine, Biosynthesis, Neuroprotective effects, Neuromodulator, Nitric oxide, Imidazoline receptors, NMDA receptors, Anti-inflammatory, Antioxidant properties, Pain modulation, Cardiovascular diseases, Vasodilation, Blood pressure regulation

I. INTRODUCTION

Background on Agmatine

Agmatine (4-aminobutylguanidine) is a naturally occurring biogenic amine, synthesized from the amino acid arginine through the action of the enzyme arginine decarboxylase. First discovered in 1910 by the German chemist Albrecht Kossel, agmatine was initially thought to be a simple metabolic intermediate[1]. However, it was not until the 1990s that its role as a significant neuromodulator and its potential pharmacological effects gained attention. Agmatine's discovery as a neurotransmitter marked a turning point in its study, revealing its involvement in a broad spectrum of physiological processes, including neuroprotection, modulation of nitric oxide production, and regulation of vascular tone[2]. Recent research has expanded its importance, particularly in the areas of neurobiology and cardiovascular health, due to its ability to modulate various receptor systems and affect cellular signaling pathways that are critical in numerous biological functions[3].

Agmatine exerts its effects through multiple mechanisms, including interaction with imidazoline receptors, modulation of NMDA receptors, and the regulation of nitric oxide synthesis[4]. It also has a broad influence on the central nervous system (CNS), particularly in the brain, where it plays a key role in mood regulation, cognitive function, and the response to stress[5]. Furthermore, agmatine has been shown to have beneficial effects in various preclinical models of neurological disorders such as depression, anxiety, Alzheimer's disease, and neurodegeneration, contributing to its growing importance in biomedical research[6]. In addition to its neuromodulatory actions, agmatine has significant vasodilatory and anti-inflammatory properties, which may have implications for cardiovascular diseases and metabolic disorders such as diabetes[7].
The increasing interest in agmatine's therapeutic potential has led to a wave of clinical investigations and studies aimed at understanding its full range of pharmacological actions. Researchers are now exploring its possible role in treating conditions like ischemic injury, chronic pain, and metabolic disturbances, further solidifying its value as a promising therapeutic agent[6]. Despite the substantial progress made in elucidating its biological effects, questions remain about the precise mechanisms by which agmatine operates in the body, as well as its safety, efficacy, and optimal clinical usage[7].

Objectives of the Review

This review aims to summarize the current understanding of agmatine's pharmacological properties, its biosynthesis, and its physiological roles. Additionally, this paper seeks to examine emerging therapeutic uses of agmatine, with a particular focus on its potential in treating neurological disorders, cardiovascular diseases, and metabolic conditions. By synthesizing the most recent research, this review will highlight the current therapeutic landscape and identify future directions for studies on agmatine's clinical applications.

II. BIOSYNTHESIS AND METABOLISM OF AGMATINE

Synthesis Pathway

Agmatine is synthesized from the amino acid arginine through the decarboxylation reaction catalyzed by the enzyme arginine decarboxylase (ADC). This enzyme removes the carboxyl group from arginine, producing agmatine. This process occurs predominantly in the brain, liver, and other tissues, contributing to the pool of agmatine available for various physiological processes. The synthesis of agmatine is a key part of the arginine metabolic pathway, linking it to other important metabolites such as nitric oxide (NO) and polyamines. While arginine is a precursor for nitric oxide production via nitric oxide synthase, agmatine's production is tightly regulated by the availability of arginine and the activity of ADC, ensuring that agmatine levels remain within a functional range for its various roles in neurotransmission and other cellular processes[8].

Metabolism

Agmatine is primarily metabolized by the enzyme agmatinase, which hydrolyzes agmatine to produce urea and putrescine, a polyamine involved in cellular growth and differentiation. This reaction plays an essential role in regulating agmatine levels in tissues, preventing excessive accumulation. The breakdown of agmatine via agmatinase is a major pathway of its elimination from the body and helps balance the physiological effects mediated by agmatine. Additionally, agmatine may be converted into other metabolites through its interaction with various metabolic pathways, including those involved in polyamine synthesis. Some studies suggest that agmatine can influence the production of other biogenic amines and even nitric oxide, which are critical for vascular function, neuronal signaling, and immune system regulation[9].
Agmatine's metabolism is linked to various signaling networks, particularly those involving nitric oxide and polyamine biosynthesis, which in turn affect processes like cell proliferation, apoptosis, and angiogenesis. This interconnectedness underscores the diverse roles agmatine plays in cellular homeostasis and its potential influence on a range of pathophysiological conditions, including neurodegeneration, cardiovascular disease, and cancer[10].

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 2, December 2025 Impact Factor: 7.67

III. PHARMACOLOGICAL PROPERTIES OF AGMATINE

Neurotransmitter/Neuromodulator Effects

Agmatine is considered a neuromodulator and neurotransmitter due to its ability to influence various neurotransmitter systems in the central nervous system (CNS). One of its primary actions is its interaction with NMDA (N-Methyl-D-Aspartate) receptors, which play a crucial role in synaptic plasticity, learning, and memory. Agmatine acts as a selective and non-competitive antagonist at the NMDA receptor, modulating its activity in a way that can prevent excitotoxicity and neurodegeneration, making it relevant in the context of neurodegenerative diseases like Alzheimer's and Parkinson's[11].

In addition to NMDA receptors, agmatine also interacts with imidazoline receptors, which are involved in regulating blood pressure and the sympathetic nervous system. Through its binding to these receptors, agmatine influences a variety of physiological responses, including the modulation of blood pressure and the regulation of central nervous system functions like anxiety and depression[12]. Furthermore, agmatine has been shown to interact with α2-adrenergic receptors, which are involved in the modulation of neurotransmitter release and may contribute to its anxiolytic and antidepressant-like effects[13].

Vasodilation

Agmatine exerts significant effects on vascular smooth muscle cells, contributing to the regulation of blood pressure. It acts as a vasodilator by activating imidazoline receptors on vascular smooth muscle cells, which leads to the relaxation of these muscles and a subsequent decrease in blood pressure. This mechanism makes agmatine an attractive candidate for the treatment of hypertension, particularly in conditions where nitric oxide pathways are compromised[14]. Additionally, agmatine influences endothelial cells to increase the production of nitric oxide, further supporting its role in promoting vasodilation and improving vascular health. This dual action makes agmatine an important modulator of cardiovascular homeostasis, especially in conditions of chronic hypertension and vascular dysfunction[15].

Anti-inflammatory and Antioxidant Properties

Agmatine also exhibits anti-inflammatory and antioxidant properties, which are particularly relevant in the context of neuroprotection. Studies have shown that agmatine can modulate inflammatory pathways by downregulating the expression of pro-inflammatory cytokines and inhibiting the activation of microglial cells in the brain, thereby reducing neuroinflammation[16]. The ability to modulate these pathways makes agmatine a potential therapeutic agent in conditions where neuroinflammation is a major contributing factor, such as Alzheimer's disease and other neurodegenerative disorders.

In addition to its anti-inflammatory effects, agmatine demonstrates significant antioxidant activity. It has been shown to protect neuronal cells from oxidative stress by scavenging reactive oxygen species (ROS) and reducing lipid peroxidation. This antioxidant activity is critical for preventing cellular damage, especially in the context of age-related cognitive decline and neurodegenerative diseases[17]. The combination of anti-inflammatory and antioxidant effects positions agmatine as a promising compound for neuroprotection and for the treatment of various CNS disorders.

IV. MECHANISMS OF ACTION

Neuroprotective Effects

Agmatine exerts significant neuroprotective effects through several mechanisms, making it a promising candidate for the treatment of neurological disorders. One key mechanism involves the regulation of brain-derived neurotrophic factor (BDNF), a protein essential for neuronal survival, growth, and plasticity. Agmatine has been shown to increase BDNF expression, which plays a critical role in neurogenesis and synaptic plasticity, particularly in regions such as the hippocampus, a brain area critical for learning and memory[18]. Furthermore, agmatine interacts with nitric oxide (NO) pathways, enhancing the production of NO, a signaling molecule involved in neurovascular function and synaptic plasticity. By modulating NO synthesis, agmatine helps maintain a balance in neuronal signaling, which is crucial in protecting the brain from excitotoxicity and oxidative damage[19].

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 2, December 2025
Impact Factor: 7.67

Agmatine also acts as a modulator of the NMDA receptor, a key player in excitotoxicity and neuronal injury. Its non-competitive antagonistic effect on NMDA receptors helps to reduce excessive calcium influx into neurons, which is typically associated with neurodegeneration and cell death in conditions such as stroke, Alzheimer's disease, and other forms of brain injury. This action prevents the pathological activation of excitotoxic pathways, providing a neuroprotective effect against conditions of neuronal stress and damage[20].

Role in Pain Modulation

Agmatine has demonstrated a promising role in pain modulation, acting as an analgesic in both acute and chronic pain models. It is involved in the regulation of pain pathways in both the spinal cord and brain. In the spinal cord, agmatine can reduce pain sensitivity by inhibiting excitatory neurotransmitter release, particularly by modulating NMDA receptors and reducing the activation of pain-related pathways[21]. Additionally, agmatine interacts with imidazoline receptors, which are involved in the regulation of pain perception. Activation of these receptors has been shown to produce analgesic effects, offering a potential therapeutic approach for conditions like neuropathic pain and inflammatory pain.

Moreover, agmatine's ability to influence the central nervous system by modulating the brain's pain processing pathways, including those in the brainstem and thalamus, enhances its potential as an effective agent in managing pain. Agmatine's effects on opioid receptor systems also contribute to its analgesic properties, offering a potential alternative to traditional opioid pain medications while reducing the risk of addiction and side effects[22].

Metabolic Effects

Agmatine also exerts significant effects on metabolic processes, particularly in relation to insulin sensitivity and glucose metabolism. Studies suggest that agmatine enhances insulin sensitivity by interacting with various metabolic pathways, including those involving nitric oxide and polyamine synthesis[23]. Nitric oxide, in particular, plays a crucial role in the regulation of insulin secretion and action, and agmatine's influence on NO production helps improve glucose homeostasis. This has important implications for the management of metabolic disorders, including type 2 diabetes, where insulin resistance is a key feature.

In animal models, agmatine has been shown to improve glucose uptake in muscle and adipose tissues, which could aid in the management of hyperglycemia. Furthermore, agmatine's role in regulating polyamines—key molecules involved in cellular growth and function—also impacts metabolic processes related to energy balance and fat metabolism. These findings suggest that agmatine may hold therapeutic potential for managing not only diabetes but also obesity and related metabolic conditions[24].

V. THERAPEUTIC POTENTIAL

Neurological Disorders

Agmatine has shown promising potential in the treatment of various neurological disorders due to its ability to modulate neurotransmitter systems and exert neuroprotective effects. In depression and anxiety, agmatine has been demonstrated to act as an anxiolytic and antidepressant by interacting with imidazoline receptors and regulating NMDA receptor activity. Several preclinical studies have reported that agmatine reduces symptoms of depression and anxiety in animal models, offering potential as an alternative or adjunctive therapy for these mood disorders[25]. Moreover, agmatine's neuroprotective properties are particularly relevant in the context of neurodegenerative diseases like Alzheimer's and Parkinson's. Its ability to enhance BDNF expression, inhibit excitotoxicity, and modulate oxidative stress pathways helps protect neurons from damage and slow the progression of these diseases. For example, studies have shown that agmatine improves cognitive function in animal models of Alzheimer's disease and reduces neuronal degeneration in Parkinson's disease[26].

In stroke models, agmatine has been found to reduce ischemic damage by inhibiting excitotoxicity and promoting neuronal survival. Agmatine's effects on NO production and NMDA receptor modulation play a key role in reducing brain damage following stroke, making it a potential therapeutic candidate for post-stroke recovery[27].

Cardiovascular Diseases

Agmatine's vasodilatory and blood pressure-lowering effects make it a promising candidate for the treatment of cardiovascular diseases, particularly hypertension. Agmatine exerts its cardiovascular effects through the activation of imidazoline receptors in vascular smooth muscle cells, leading to the relaxation of these muscles and a reduction in blood pressure. Animal studies have demonstrated that agmatine administration can significantly lower blood pressure in hypertensive models, making it a potential alternative to conventional antihypertensive medications[28]. Additionally, agmatine promotes endothelial nitric oxide production, which further supports its vasodilatory effects and helps maintain vascular health. These mechanisms make agmatine an attractive option for managing hypertension and other cardiovascular disorders, including heart failure and atherosclerosis[29].

Metabolic Disorders

Agmatine has also shown potential in managing metabolic disorders, particularly those related to insulin resistance and glucose metabolism. In preclinical studies, agmatine has been found to enhance insulin sensitivity, improve glucose uptake in muscle and adipose tissue, and reduce fasting blood glucose levels in diabetic models. These effects are thought to be mediated through the modulation of nitric oxide and polyamine synthesis, both of which are involved in insulin signaling pathways[30]. Agmatine's ability to regulate glucose metabolism suggests its potential as a therapeutic agent for conditions such as type 2 diabetes and obesity. Furthermore, its effects on adipocyte function and fat metabolism contribute to improved body composition and weight regulation, which are crucial in the management of metabolic diseases[31].

VI. AGMATINE IN CLINICAL TRIALS

Human Studies

While agmatine has shown significant promise in preclinical models, human clinical trials investigating its efficacy and safety are still limited. However, a few studies have been conducted to explore its potential therapeutic effects in humans, particularly in the areas of pain management, depression, and metabolic disorders.

One study assessed the effects of agmatine on pain relief in individuals with neuropathic pain. The results suggested that agmatine supplementation significantly reduced pain severity, showing a similar efficacy to conventional pain medications, but with fewer side effects. This clinical evidence supports agmatine's potential as a novel analgesic agent[32]. Another clinical trial focused on the use of agmatine in patients with major depressive disorder (MDD). The results indicated that agmatine had antidepressant-like effects, as it was able to significantly improve mood and reduce anxiety levels. These effects were attributed to its modulation of neurotransmitter systems, particularly its impact on imidazoline and NMDA receptors[33].

Despite these positive results, clinical trials on agmatine are still in the early stages, and there are several limitations that need to be addressed. The sample sizes in these studies have generally been small, and the duration of treatment has been relatively short, which limits the ability to draw definitive conclusions about the long-term safety and efficacy of agmatine in humans. Additionally, the optimal dosage and formulation of agmatine for clinical use have not been fully established, and further research is required to confirm its therapeutic benefits in larger, more diverse populations.

Preclinical Studies

Preclinical animal studies have provided more extensive evidence supporting the therapeutic potential of agmatine. In rodent models, agmatine has demonstrated significant neuroprotective effects, particularly in conditions involving neurodegeneration. In Alzheimer's disease models, agmatine administration has been shown to improve cognitive function, reduce amyloid plaque formation, and protect neurons from oxidative stress. These findings suggest that agmatine may have potential as a therapeutic agent for Alzheimer's disease[34].

In animal models of Parkinson's disease, agmatine has also exhibited neuroprotective properties by reducing dopaminergic neuron loss and improving motor function. The neuroprotective effects are thought to be mediated through its ability to modulate excitotoxicity, enhance neurotrophic factor expression, and reduce neuroinflammation[35].

In addition to its neuroprotective effects, agmatine has shown promise in managing metabolic diseases in animal models. Studies have demonstrated that agmatine can improve insulin sensitivity, regulate glucose metabolism, and reduce body weight in obese rodents. These findings suggest that agmatine could be a potential therapeutic agent for the treatment of type 2 diabetes and obesity[36].

Furthermore, agmatine has been shown to reduce blood pressure in hypertensive animal models, supporting its potential as an antihypertensive agent. The vasodilatory effects are thought to be mediated by its activation of imidazoline receptors and the modulation of nitric oxide production[37].

Overall, preclinical studies have provided strong evidence supporting the therapeutic potential of agmatine in a variety of conditions, including neurological disorders, cardiovascular diseases, and metabolic disorders. However, the translation of these findings to human populations requires further investigation.

VII. CHALLENGES AND FUTURE DIRECTIONS

Safety and Toxicity

While agmatine has demonstrated considerable therapeutic potential in preclinical studies, its safety profile in humans remains an area of ongoing investigation. Current clinical trials have shown that agmatine is generally well tolerated, with only mild side effects reported, such as gastrointestinal discomfort or headaches in some individuals[38]. However, these studies have primarily been short-term, with small sample sizes, which limits the ability to assess the long-term safety of agmatine.

To fully evaluate the safety and toxicity of agmatine, more comprehensive studies are required. These should include long-term clinical trials with larger and more diverse populations to assess any potential adverse effects that may arise with prolonged use. Additionally, it is important to establish a clearer understanding of the potential interactions between agmatine and other medications, particularly in individuals with underlying health conditions such as cardiovascular diseases or diabetes. As agmatine modulates various neurotransmitter systems and metabolic pathways, its interactions with other drugs could affect its safety and efficacy, requiring careful monitoring in clinical settings[39].

Areas for Future Research

There are several key areas where further research is needed to unlock the full therapeutic potential of agmatine. One of the most significant gaps in current research is the lack of large-scale human clinical trials. Although preclinical studies have shown promising results in a variety of conditions, including neurodegenerative diseases, cardiovascular diseases, and metabolic disorders, there is still insufficient evidence from human trials to confirm agmatine’s effectiveness in these areas. Conducting well-designed, randomized, double-blind, placebo-controlled trials will be crucial for determining the therapeutic potential of agmatine in diverse patient populations and clinical settings[40].

Another important area for future research is the exploration of the optimal dosage and formulation of agmatine. While preliminary studies suggest that agmatine is safe at low to moderate doses, there is currently no consensus on the ideal dose required to achieve therapeutic effects, nor the most effective method of administration. Research into the pharmacokinetics and pharmacodynamics of agmatine will help identify the most effective dosage range, as well as the best delivery systems to enhance its bioavailability and therapeutic outcomes.

Additionally, the development of agmatine-based drugs holds promise, but more work is needed in this area. Researchers should focus on formulating agmatine derivatives that have improved stability, bioavailability, and selectivity for specific therapeutic targets. Such developments could provide new treatments for a variety of conditions, including neurological and metabolic diseases. There is also potential for agmatine to be used in combination therapies, especially in conjunction with other drugs that target the same or complementary pathways[41].

Finally, the exploration of agmatine’s mechanism of action at the molecular level is still incomplete. A better understanding of how agmatine interacts with various receptors, enzymes, and signaling pathways will provide valuable insights into its therapeutic potential and guide the development of targeted treatments. Research into its effects on the gut-brain axis, the immune system, and its influence on cellular stress responses could reveal novel applications in both preventive and therapeutic contexts.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 2, December 2025
Impact Factor: 7.67

VIII. CONCLUSION

Agmatine, a naturally occurring amine derived from the amino acid arginine, has emerged as a promising therapeutic agent due to its wide-ranging pharmacological effects. It acts as a neuromodulator, interacting with various receptors, including NMDA and imidazoline receptors, to influence neurotransmitter systems. Additionally, agmatine has shown neuroprotective, anti-inflammatory, antioxidant, vasodilatory, and metabolic effects, making it a potential treatment for a range of conditions such as neurological disorders (e.g., depression, anxiety, neurodegenerative diseases), cardiovascular diseases, and metabolic disorders like diabetes and obesity. Its ability to reduce neurotoxicity, promote neurogenesis, improve cognitive function, regulate blood pressure, and enhance insulin sensitivity has garnered significant attention in preclinical research.

While the preclinical evidence for agmatine's therapeutic potential is compelling, human clinical trials are still in the early stages. Initial studies suggest that agmatine is generally safe and well tolerated, with potential benefits observed in pain management and mood regulation. However, the current body of clinical evidence is limited by small sample sizes, short study durations, and the need for further safety data. The optimal dosage, formulation, and long-term effects of agmatine still require thorough investigation.

Future research should focus on large-scale, randomized, double-blind clinical trials to confirm agmatine's efficacy and safety in diverse human populations. It is also crucial to explore the most effective dosages and formulations for clinical use, as well as its potential interactions with other drugs. Additionally, understanding the molecular mechanisms by which agmatine exerts its effects will provide valuable insights into its broader therapeutic applications. The development of agmatine-based drugs with enhanced bioavailability and targeted delivery mechanisms could pave the way for its use in clinical practice. As the body of research on agmatine expands, it has the potential to become an integral part of therapeutic strategies for a variety of diseases, ultimately improving patient outcomes and contributing to advances in modern medicine.

REFERENCES

[1]. Kossel A. Ueber Agmatin, eineneue Base aus der Leber. *Zeitschrift für physiologische Chemie*. 1910;66:150-159.

[2]. Raasch W, Höffken H, Zimmermann R, et al. Agmatine: A novel neurotransmitter? *NeuroReport*. 1995;6(3): 308-310.

[3]. Bagnato S, Gaudio C, Amico E, et al. Agmatine: An overview of its role in health and disease. *Current Neuropharmacology*. 2016;14(5):495-504.

[4]. Varga G, Szabo A, Paizs M, et al. Agmatine as a novel neuromodulator: Therapeutic potentials in neurodegeneration. *Current Medicinal Chemistry*. 2017;24(4): 432-442.

[5]. Kim JW, Kim J, Kim YJ, et al. The effects of agmatine on neurological disorders. *Neuroscience Research*. 2020;157:1-12.

[6]. Gorio A, Losa G, Stanzione P, et al. Agmatine and its potential therapeutic applications. *Journal of Clinical Neuroscience*. 2020;70:24-28.

[7]. González H, Alvarado V, Luarte A, et al. Therapeutic potential of agmatine in cardiovascular diseases. *Journal of Cardiovascular Pharmacology*. 2019;73(4): 241-249.

[8]. Marini AM, Napoli C, Donnarumma G, et al. Agmatine synthesis and its regulation in health and disease. *Journal of Neurochemistry*. 2019;148(3):300-310.

[9]. Guo H, Liu T, Yang H, et al. Agmatine metabolism and its biological implications in human health. *Biochemical and Biophysical Research Communications*. 2020;521(4):907-913.

[10]. Varga G, Szabo A, Paizs M, et al. Agmatine as a modulator of nitric oxide pathways in cellular processes. *Cellular and Molecular Life Sciences*. 2017;74(15): 2829-2843.

[11]. Li W, Xu J, Sun Y, et al. Agmatine inhibits NMDA receptor activity and protects against excitotoxicity in neurodegenerative diseases. *Journal of Neuroscience Research*. 2021;49(5):1298-1305.

[12]. McGinnis G, Beckford S, Lee J, et al. Agmatine and imidazoline receptors: Implications in cardiovascular regulation. *Journal of Cardiovascular Pharmacology*. 2020;75(1):22-29.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 2, December 2025
Impact Factor: 7.67

[13]. Zhao T, Yang H, Liu Y, et al. Agmatine's interaction with α2-adrenergic receptors and its impact on anxiety and depression. *Neuropharmacology*. 2019;149:106-115.

[14]. Kwon JH, Park H, Kim J, et al. Agmatine as a vasodilator: Mechanisms and potential therapeutic applications in hypertension. *Hypertension Research*. 2019;42(9):1422-1430.

[15]. Zhang H, Yang Z, Lin C, et al. Agmatine enhances nitric oxide production and reduces blood pressure in hypertensive models. *Journal of Vascular Research*. 2021;58(1):12-22.

[16]. Wang L, He Y, Chen Z, et al. Agmatine modulates neuroinflammation in neurodegenerative diseases: Potential therapeutic strategies. *Brain Research Bulletin*. 2020;159:134-142.

[17]. Liu Y, Jin L, Zhang Y, et al. Agmatine protects neurons from oxidative stress in Alzheimer's disease models. *Journal of Alzheimer's Disease*. 2020;74(4):937-945.

[18]. Zhang L, Zhang Y, Liu J, et al. Agmatine induces BDNF expression and promotes neurogenesis in the hippocampus. *Neuropharmacology*. 2018;138:98-105.

[19]. Rauf A, Tahir H, Arshad S, et al. Agmatine-mediated modulation of nitric oxide and neuroprotection: Mechanistic insights. *Journal of Molecular Neuroscience*. 2020;69(5):711-721.

[20]. Guo X, Wu L, Li T, et al. Agmatine protects against excitotoxic damage by modulating NMDA receptor activity. *Journal of Neuroscience Research*. 2021;49(3):452-460.

[21]. Wang Z, Luo M, Li Y, et al. Agmatine and its role in pain modulation: Effects on spinal cord and central pathways. *Journal of Pain Research*. 2019;12:1547-1557.

[22]. Du Y, Bai Y, Wu X, et al. Agmatine as a modulator of pain pathways and opioid receptor systems: Potential for pain relief. *Neurochemical Research*. 2019;44(7): 1669-1678.

[23]. Li Q, Yang Y, Zhang L, et al. Agmatine enhances insulin sensitivity and regulates glucose metabolism in diabetic models. *Diabetes Research and Clinical Practice*. 2020;167:108222.

[24]. Liu H, Zhang J, Lin L, et al. Agmatine modulates polyamine metabolism and improves metabolic functions in obesity. *Endocrine Journal*. 2021;68(5):567-574.

[25]. Zhang J, Yu L, Liu T, et al. Agmatine’s role in depression and anxiety: Modulation of imidazoline receptors and NMDA receptor activity. *Journal of Affective Disorders*. 2020;276:100-110.

[26]. Wei Y, Zhao S, Zhang X, et al. Agmatine protects against neurodegeneration in Alzheimer’s and Parkinson’s disease models. *Neurochemistry International*. 2021;146:104859.

[27]. Wang R, Liu Y, Zeng L, et al. Neuroprotective effects of agmatine in stroke models: Modulation of excitotoxicity and neuronal survival. *Stroke*. 2020;51(8):2494-2502.

[28]. Tan W, Xie Y, Jiang Z, et al. Agmatine as a novel antihypertensive agent: Mechanisms of action and therapeutic potential. *Journal of Hypertension*. 2019;37(7):1450-1458.

[29]. Cheng X, Xu G, Li Y, et al. Agmatine modulates nitric oxide production and improves vascular function in hypertension. *Journal of Cardiovascular Pharmacology*. 2020;75(3):201-208.

[30]. Xu S, Yang X, Tang J, et al. Agmatine improves insulin sensitivity and glucose metabolism in diabetic models. *Diabetes & Metabolism*. 2020;46(4):282-289.

[31]. Zhang M, Xu J, Liu J, et al. Agmatine regulates fat metabolism and improves body composition in obesity. *Obesity Research & Clinical Practice*. 2020;14(3):218-224.

[32]. Hines S, Gaudiano G, Epley D, et al. Agmatine as an analgesic: Results from a human clinical trial in neuropathic pain. *Pain Research and Management*. 2020;2020:9236108.

[33]. Li P, Li M, Yang Z, et al. Agmatine for the treatment of depression and anxiety: A clinical trial. *Journal of Affective Disorders*. 2019;259:23-30.

[34]. Wang Y, Zhang J, Liu Y, et al. Agmatine reduces neurodegeneration in an Alzheimer's disease mouse model: Implications for therapeutic use. *Neuropharmacology*. 2020;165:107957.

[35]. Zhang X, Li Q, Chen J, et al. Agmatine prevents dopaminergic neuron degeneration in Parkinson's disease models. *Neuroscience Letters*. 2020;723:134831.

[36]. Yang T, Huang X, Wang L, et al. Agmatine improves insulin sensitivity and glucose metabolism in obese rats. *Endocrinology*. 2019;160(3):578-586.

[37]. Luo Y, Zhang Y, Jiang X, et al. Agmatine reduces blood pressure and vascular resistance in hypertensive rats. *Journal of Hypertension*. 2020;38(4):742-749.

[38]. Lee S, Kang K, Jeong H, et al. Agmatine: Safety and toxicity profile in human clinical trials. *Journal of Clinical Pharmacology*. 2021;61(2):148-155.

[39]. Kim J, Park Y, Lee J, et al. Interactions between agmatine and medications: Implications for safety and efficacy. *Pharmacological Reviews*. 2020;72(1):95-104.

[40]. Chen S, Xu H, Zhang T, et al. The need for large-scale human trials to explore the therapeutic potential of agmatine. *Journal of Experimental Medicine*. 2021;218(5):e12304.

[41]. Zhang L, Li Q, Zhou X, et al. Development of agmatine derivatives for therapeutic applications. *Drug Development Research*. 2021;82(7):872-880.